The health(y) cost of erythropoietin in orthopedic surgery;Le coût élevé de l'érythropoïétine en chirurgie orthopédique

Canadian Journal of Anesthesia

Volumn 52, Issue 4, 2005, Pages 347-351

  Fergusson, Dean A ^a   Hébert, Paul ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ANEMIA; BLOOD DONOR; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CREUTZFELDT JAKOB DISEASE; DATA ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SAFETY; EDITORIAL; ERYTHROCYTE TRANSFUSION; HEMATOCRIT; HIP ARTHROPLASTY; HUMAN; INFECTION PREVENTION; LENGTH OF STAY; META ANALYSIS; MOBILIZATION; ORTHOPEDIC SURGERY; PATIENT ATTITUDE; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURVIVAL; SYSTEMATIC REVIEW; TIME; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 19944366646     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03016274     Document Type: Editorial

References (15)

1. Feagan BG, Wong CJ, Kirkley A, et al. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial. Ann Intern Med 2000; 133: 845-54.
2. Laupacis A, Feagan B, Wong C. Effectiveness of perioperative recombinant human erythropoietin in elective hip replacement. COPES Study Group. Lancet 1993; 342: 378.
3. Faris PM, Ritter MA, Abels RI. The effects of recombinant human erythropoietin on perioperative transfusion requirements in patients having a major orthopaedic operation. The American Erythropoietin Study Group. J Bone Joint Surg Am 1996; 78: 62-72.
4. Laupacis A, Fergusson D. Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. The International Study of Perioperative Transfusion (ISPOT) Investigators. Transfus Med 1998; 8: 309-17.
5. Fergusson D, Blair A, Henry D, et al. Technologies to minimize blood transfusion in cardiac and orthopedic surgery. Results of a practice variation survey in nine countries. International Study of Peri-operative Transfusion (ISPOT) Investigators. Int J Technol Assess Health Care 1999; 15: 717-28.
6. Graham ID, Fergusson D, McAuley L, Laupacis A. The use of technologies to minimize exposure to perioperative allogeneic blood transfusion in elective surgery. A survey of Canadian hospitals. Int J Technol Assess Health Care 2000; 16: 228-41.
7. Faught C, Wells P, Fergusson D, Laupacis A. Adverse effects of methods for minimizing perioperative allogeneic transfusion: a critical review of the literature. Transfus Med Rev 1998; 12: 206-25.
8. de Andrade JR, Frei D, Guilfoyle M. Integrated analysis of thrombotic/vascular event occurrence in epoetin alfa-treated patients undergoing major, elective orthopedic surgery. Orthopedics 1999; 22(1 Suppl): s113-8.
9. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Canadian Pharmaceutical Association, 2004.
10. Coyle D, Lee KM, Fergusson DA, Laupacis A. Economic analysis of erythropoietin use in orthopaedic surgery. Transfus Med 1999; 9: 21-30.
11. Karkouti K, McCluskey SA, Evans L, Mahomed N, Ghannam M, Davey R. Erythropoietin is an effective clinical modality for reducing RBC transfusion in joint surgery. Can J Anesth 2005; 52: 362-8.
12. Amin AM, Hebert PC, Fergusson DA. The societal cost of allogeneic RBC transfusion in Canada. Transfusion 2003; 43(Suppl): 154A (abstract).
13. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003; 17: 120-62.
14. Germain M, Gelinas S, Delage G. Estimates of risk of window-period transmission of blood-borne viral diseases in Quebec (Letter). CMAJ 2004; 170: 1077-8.
15. Chiavetta JA, Escobar M, Newman A, et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 2003; 169: 767-73.